Rockefeller Capital Management L.P. Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

Rockefeller Capital Management L.P. decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 375,013 shares of the medical research company's stock after selling 7,516 shares during the period. Rockefeller Capital Management L.P. owned about 0.21% of IQVIA worth $88,869,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of IQV. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp bought a new stake in IQVIA in the 3rd quarter worth about $28,000. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the 2nd quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the second quarter valued at approximately $29,000. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research report on Friday, November 1st. Truist Financial cut their price target on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a report on Monday, November 4th. Barclays decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a "buy" rating and a $276.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average target price of $256.50.

IQVIA Price Performance

Shares of IQVIA stock traded down $0.59 on Friday, reaching $200.84. The stock had a trading volume of 513,712 shares, compared to its average volume of 1,174,636. The business's 50 day moving average is $219.50 and its two-hundred day moving average is $226.40. The company has a market cap of $36.45 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.